SAVOR-TIMI 53

SAVOR-TIMI 53 was a randomized, double-blind, placebo-controlled trial to assess the cardiovascular efficacy and safety of saxaglipitin, a DPP-4 inhibitor, when added to standard of care in patients with type 2 diabetes mellitus.

MAIN RESULTS:
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
SAVOR-TIMI 53

PRESENTATIONS

TIMI 53 Slides
HF Risk Stratification and Efficacy of SGLT2 Inhibitors in Patients with T2DM (Berg ESC 2019)
SAVOR DM Genetics (Marston AHA 2019)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)

PUBLICATIONS

Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease

Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease

Response by Bergmark et al to Letter Regarding Article, “Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial”

Performance of a Genome-Wide Polygenic Risk Score to Predict Coronary Events in Patients With Diabetes Without Prior Myocardial Infarction

Genome-Wide Association Study of Over One Million Participants Identifies 49 Novel Loci Associated With Coronary Artery Disease

Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial

Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53

Natriuretic Peptides Versus A Clinical History Of Heart Failure For Risk Prediction In Patients With Diabetes

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk

Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER

Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial

Blood Pressure, Subclinical Myocardial Injury And Cardiovascular Outcomes Among Patients With Diabetes And High Cardiovascular Risk: Observations From The SAVOR-TIMI 53 Trial

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study

Risk Stratification With The Timi Risk Score For Secondary Prevention Among Patients With Diabetes And Elevated Cardiovascular Risk

Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial

Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial

Patterns Of Aspirin Utilization And Outcomes Among Patients With Diabetes Mellitus: A Propensity Score Matched Analysis From The SAVOR-TIMI 53 Trial

Clinical Factors Associated With Sudden Cardiac Death In Type 2 Diabetes: Insights From The SAVOR-TIMI 53 Trial

Response to: ‘baseline differences in SAVOR trial’ – prespecified vs. post hoc analysis – a potential source of bias

Frequency of Cancer Events with Saxagliptin in the SAVOR-TIMI 53 Trial

Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial

Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

Impact of treatment with saxagliptin on glycaemic stability and beta-cell function in the SAVOR-TIMI 53 study

Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR – TIMI 53 Randomized Trial

Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin

Baseline characteristics of patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR) – TIMI 53 Trial

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close